{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:34:47Z","timestamp":1793331287457,"version":"4.5.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Enfortumab vedotin (EV) was approved for patients with metastatic urothelial carcinoma (mUC) who progressed after anticancer therapy on September 2021 in Japan. The association between the occurrence of EV-related side effects and clinical outcome remains to be elucidated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We identified 97 mUC patients treated with EV therapy at our five institutions from the date of approval to March 2023. The median follow-up period was 7.0\u00a0months. We retrospectively analyzed the efficacy and safety of EV.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The median age of the patients was 71\u00a0years old, 39% had PS of 1 or more, and 56.7% had primary tumor in upper urinary tract. Overall response rate (ORR) to EV therapy, median progression-free survival (PFS), and overall survival (OS) were 43.3%, 7.52\u00a0months, and 12.78\u00a0months, respectively. Any grade of treatment-related skin disorder, dysgeusia, peripheral neuropathy, gastrointestinal disorder, and hyperglycemia occurred in 61 (62.9%), 36 (37.1%), 34 (35.1%), 29 (29.9%), and 18 (18.6%) patients, respectively. The patients with EV-associated peripheral neuropathy had significantly higher ORR (58.8% vs. 34.9%, P\u00a0=\u00a0.032) and longer median PFS (8.05 vs. 6.31\u00a0months, P\u00a0=\u00a0.017) and OS (not reached vs. 11.57\u00a0months, P\u00a0=\u00a0.008, respectively) than those without. The occurrence of peripheral neuropathy after EV treatment and the presence of peritoneal dissemination were factors independently associated with PFS (hazard ratio\u00a0=\u00a00.46, P\u00a0=\u00a0.008 and hazard raito = 3.83, P = .004, respectively) and OS (hazard ratio\u00a0=\u00a00.30, P\u00a0=\u00a0.005 and hazard raito = 4.53, P = .002, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The occurrence of EV-related peripheral neuropathy might be associated with the efficacy of EV therapy in mUC patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyae082","type":"journal-article","created":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T13:18:57Z","timestamp":1719667137000},"page":"1194-1200","source":"Crossref","is-referenced-by-count":19,"title":["Association between response to enfortumab vedotin and peripheral neuropathy in urothelial carcinoma patients: a multicenter retrospective study"],"prefix":"10.1093","volume":"54","author":[{"given":"Nozomi","family":"Hayakawa","sequence":"first","affiliation":[{"name":"Department of Urology, St. Marianna University School of Medicine , Kanagawa, Kanagawa ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Urology, St. Marianna University School of Medicine , Kanagawa, Kanagawa ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Uro-Oncology, Saitama Medical University International Medical Center , Saitama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Division of Urology, Shizuoka Cancer Center , Suntougun, Shizuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Ikarashi","sequence":"additional","affiliation":[{"name":"Department of Urology, Iwate Medical University School of Medicine , Iwate ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Urology, Nippon Medical School , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimitsugu","family":"Usui","sequence":"additional","affiliation":[{"name":"Division of Urology, Shizuoka Cancer Center , Suntougun, Shizuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2720-9640","authenticated-orcid":false,"given":"Wataru","family":"Obara","sequence":"additional","affiliation":[{"name":"Department of Urology, Iwate Medical University School of Medicine , Iwate ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Oyama","sequence":"additional","affiliation":[{"name":"Department of Uro-Oncology, Saitama Medical University International Medical Center , Saitama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Urology, Nippon Medical School , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,29]]},"reference":[{"key":"2024110408211759200_ref1","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"2024110408211759200_ref2","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"2024110408211759200_ref3","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"2024110408211759200_ref4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41585-020-00394-5","article-title":"The biology and rationale of targeting nectin-4 in urothelial carcinoma","volume":"18","author":"Heath","year":"2021","journal-title":"Nat Rev Urol"},{"key":"2024110408211759200_ref5","doi-asserted-by":"crossref","first-page":"43205","DOI":"10.1074\/jbc.M103810200","article-title":"Nectin4\/PRR4, a new afadin-associated member of the nectin family that trans-interacts with nectin1\/PRR1 through V domain interaction","volume":"276","author":"Reymond","year":"2001","journal-title":"J Biol Chem"},{"key":"2024110408211759200_ref6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrm2457","article-title":"Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation","volume":"9","author":"Takai","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2024110408211759200_ref7","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"2024110408211759200_ref8","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024110408211759200_ref9","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/cncr.34057","article-title":"Efficacy of enfortumab vedotin in advanced urothelial cancer: analysis from the urothelial cancer network to investigate therapeutic experiences (UNITE) study","volume":"128","author":"Koshkin","year":"2022","journal-title":"Cancer"},{"key":"2024110408211759200_ref10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.euros.2023.04.018","article-title":"Enfortumab vedotin in metastatic urothelial carcinoma: survival and safety in a European Multicenter real-world patient cohort","volume":"53","author":"Zsch\u00e4bitz","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"2024110408211759200_ref11","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1002\/cam4.5165","article-title":"Japanese subgroup analysis of EV-301: an open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma","volume":"12","author":"Matsubara","year":"2023","journal-title":"Cancer Med"},{"key":"2024110408211759200_ref12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrclinonc.2010.228","article-title":"Mitosis is not a key target of microtubule agents in patient tumors","volume":"8","author":"Komlodi-Pasztor","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"2024110408211759200_ref13","doi-asserted-by":"crossref","first-page":"100090","DOI":"10.1016\/j.esmoop.2021.100090","article-title":"Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study","volume":"6","author":"Ruiz-Ba\u00f1obre","year":"2021","journal-title":"ESMO Open"},{"key":"2024110408211759200_ref14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.euros.2023.01.002","article-title":"Enfortumab vedotin-related cutaneous toxicity and radiographic response in patients with urothelial cancer: a single-center experience and review of the literature","volume":"49","author":"Vlachou","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"2024110408211759200_ref15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejca.2015.10.017","article-title":"Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: a subset analysis from a randomised phase III trial (MPACT)","volume":"52","author":"Goldstein","year":"2016","journal-title":"Eur J Cancer"},{"key":"2024110408211759200_ref16","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/bjc.2011.256","article-title":"Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer","volume":"105","author":"Lee","year":"2011","journal-title":"Br J Cancer"},{"key":"2024110408211759200_ref17","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.3390\/jcm10091846","article-title":"Association between low-grade chemotherapy-induced peripheral neuropathy (CINP) and survival in patients with metastatic adenocarcinoma of the pancreas","volume":"10","author":"Catalano","year":"2021","journal-title":"J Clin Med"},{"key":"2024110408211759200_ref18","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s10147-024-02481-8","article-title":"Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study","volume":"29","author":"Taoka","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"2024110408211759200_ref19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/jjco\/hyad170","article-title":"Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort","volume":"54","author":"Miyake","year":"2024","journal-title":"Jpn J Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/11\/1194\/60343197\/hyae082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/11\/1194\/60343197\/hyae082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T08:23:24Z","timestamp":1730708604000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/54\/11\/1194\/7701627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,29]]},"references-count":19,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6,29]]},"published-print":{"date-parts":[[2024,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae082","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,6,29]]}}}